Profile data is unavailable for this security.
About the company
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing, marketing and selling of a broad range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The Company operates through three segments, such as Injectables, Generics and Branded. The Injectables business develops and manufactures generic injectable products, which are primarily used in hospitals. The Generics business develops and manufactures oral and other non-injectable generic products. The Branded business develops and manufactures branded generics and markets and sells in-licensed patented products in Middle East/North Africa (MENA). The Company’s products are sold in the retail and hospital markets. It also markets its products in Canada, which includes approximately 25 sterile injectable products, three in-licenced ophthalmic products and a pipeline of seven additional products.
- Revenue in GBP (TTM)2.14bn
- Net income in GBP352.09m
- LocationHikma Pharmaceuticals PLC1 New Burlington PlaceLONDON W1S 2HRUnited KingdomGBR
- Phone+44 207 399 2760
- Fax+44 207 399 2761
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|HIK:LSE since |
|Teligent Inc-Sterile Injectable Assets||Deal completed||17 Jan 2022||17 Jan 2022Deal completed||-18.70%||36.45m|
|CUSTOpharm Inc||Deal completed||27 Sep 2021||27 Sep 2021Deal completed||-29.95%||425.00m|